COX2/mPGES1/PGE2 pathway regulates PD-L1 expression in tumor-associated macrophages and myeloid-derived suppressor cells

Proceedings of the National Academy of Sciences of the United States of America

Volumn 114, Issue 5, 2017, Pages 1117-1122

  Prima, Victor ^a   Kaliberova, Lyudmila N ^b   Kaliberov, Sergey ^b   Curiel, David T ^b   Kusmartsev, Sergei ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY   (United States)

Author keywords

Bone marrow; Myeloid cells; PD L1; PGE2metabolism; Tumor associated macrophages

Indexed keywords

15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; PROGRAMMED DEATH 1 LIGAND 1; PROSTAGLANDIN E SYNTHASE 1; PROSTAGLANDIN E2; 15-HYDROXYPROSTAGLANDIN DEHYDROGENASE; CD274 PROTEIN, MOUSE; PROSTAGLANDIN E SYNTHASE; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; PTGS2 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLADDER TUMOR; BONE MARROW CELL; CD8+ T LYMPHOCYTE; CELL LINEAGE; CELL STRUCTURE; COCULTURE; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; MYELOID-DERIVED SUPPRESSOR CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; ANIMAL; BIOSYNTHESIS; C3H MOUSE; CELL COMMUNICATION; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; MACROPHAGE; METABOLISM; NONOBESE DIABETIC MOUSE; PATHOLOGY; PHYSIOLOGY; SCID MOUSE; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; B7-H1 ANTIGEN; BONE MARROW CELLS; CELL COMMUNICATION; CELL LINE, TUMOR; COCULTURE TECHNIQUES; CYCLOOXYGENASE 2; DINOPROSTONE; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROGRAFTS; HUMANS; HYDROXYPROSTAGLANDIN DEHYDROGENASES; MACROPHAGES; MICE; MICE, INBRED C3H; MICE, INBRED NOD; MICE, SCID; MYELOID-DERIVED SUPPRESSOR CELLS; PROSTAGLANDIN ANTAGONISTS; PROSTAGLANDIN-E SYNTHASES; URINARY BLADDER NEOPLASMS;

EID: 85010987063     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1612920114     Document Type: Article

References (31)

1. Chen L, Han X (2015) Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest 125(9):3384-3391.
2. Ansell SM, et al. (2015) PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 372(4):311-319.
3. Robert C, et al.; KEYNOTE-006 investigators (2015) Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372(26):2521-2532.
4. Garon EB, et al.; KEYNOTE-001 Investigators (2015) Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372(21):2018-2028.
5. Brahmer JR, et al. (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366(26):2455-2465.
6. Powles T, et al. (2014) MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515(7528):558-562.
7. Moussa M, Omran Z, Nosseir M, Lotfy A, Swellam T (2009) Cyclooxygenase-2 expression on urothelial and inflammatory cells of cystoscopic biopsies and urine cytology as a possible predictive marker for bladder carcinoma. APMIS 117(1):45-52.
8. Eruslanov E, et al. (2012) Circulating and tumor-infiltrating myeloid cell subsets in patients with bladder cancer. Int J Cancer 130(5):1109-1119.
9. + cells in bladder cancer is subtype specific and affects the outcome of patients with muscle-invasive tumors. Urol Oncol 32(6):791-797.
10. Kusmartsev S, Vieweg J (2009) Enhancing the efficacy of cancer vaccines in urologic oncology: new directions. Nat Rev Urol 6(10):540-549.
11. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V (2012) Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 12(4):253-268.
12. Egawa M, et al. (2013) Inflammatory monocytes recruited to allergic skin acquire an anti-inflammatory M2 phenotype via basophil-derived interleukin-4. Immunity 38(3):570-580.
13. Kusmartsev S, Gabrilovich DI (2005) STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion. J Immunol 174(8):4880-4891.
14. Dong H, et al. (2002) Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8(8):793-800.
15. Wang D, Dubois RN (2010) Eicosanoids and cancer. Nat Rev Cancer 10(3):181-193.
16. Rodriguez PC, et al. (2005) Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J Exp Med 202(7):931-939.
17. Sinha P, Clements VK, Fulton AM, Ostrand-Rosenberg S (2007) Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res 67(9):4507-4513.
18. Kalinski P (2012) Regulation of immune responses by prostaglandin E2. J Immunol 188(1):21-28.
19. Samuelsson B, Morgenstern R, Jakobsson PJ (2007) Membrane prostaglandin E synthase-1: a novel therapeutic target. Pharmacol Rev 59(3):207-224.
20. Tai HH, Cho H, Tong M, Ding Y (2006) NAD+-linked 15-hydroxyprostaglandin dehydrogenase: structure and biological functions. Curr Pharm Des 12(8):955-962.
21. Kömhoff M, et al. (2000) Enhanced expression of cyclooxygenase-2 in high grade human transitional cell bladder carcinomas. Am J Pathol 157(1):29-35.
22. Tseng-Rogenski S, et al. (2010) Loss of 15-hydroxyprostaglandin dehydrogenase expression contributes to bladder cancer progression. Am J Pathol 176(3):1462-1468.
23. 2 catabolism in myeloid cells. J Leukoc Biol 88(5):839-848.
24. Alberti MO, et al. (2013) A myeloid cell-binding adenovirus efficiently targets gene transfer to the lung and escapes liver tropism. Gene Ther 20(7):733-741.
25. Lu ZH, et al. (2014) The myeloid-binding peptide adenoviral vector enables multiorgan vascular endothelial gene targeting. Lab Invest 94(8):881-892.
26. Balkwill F, Charles KA, Mantovani A (2005) Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7(3):211-217.
27. Zelenay S, et al. (2015) Cyclooxygenase-dependent tumor growth through evasion of immunity. Cell 162(6):1257-1270.
28. Kurtova AV, et al. (2015) Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance. Nature 517(7533):209-213.
29. Le CP, et al. (2016) Chronic stress in mice remodels lymph vasculature to promote tumour cell dissemination. Nat Commun 7:10634.
30. Dowd NP, Scully M, Adderley SR, Cunningham AJ, Fitzgerald DJ (2001) Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo. J Clin Invest 108(4):585-590.
31. Lévesque LE, Brophy JM, Zhang B (2006) Time variations in the risk of myocardial infarction among elderly users of COX-2 inhibitors. CMAJ 174(11):1563-1569.